iBio

iBio Total Assets

The Total Assets of iBio (IBIO) as of Nov 17, 2026 is 99.11 M USD. In the previous year, Total Assets was 23.19 M USD — a change of 327.47% (higher).

Total Assets

99.11 MUSD

YoY

327.47%

Last updated:

Total Assets of iBio is 2026 99.11 M USD. Total Assets of iBio was 2025 23.19 M USD. It decreases by 327.47% higher compared to the previous year.

The iBio Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
30.59 M USD
Jan 1, 2020
94.19 M USD
Jan 1, 2021
146.97 M USD
Jan 1, 2022
99.41 M USD
Jan 1, 2023
41.21 M USD
Jan 1, 2024
28.73 M USD
Jan 1, 2025
23.19 M USD
Jan 1, 2026
99.11 M USD
The iBio Total Assets history
YEARTotal AssetsYoY
99.11 MUSD+327.47%
23.19 MUSD-19.31%
28.73 MUSD-30.27%
41.21 MUSD-58.55%
99.41 MUSD-32.36%
146.97 MUSD+56.04%
94.19 MUSD+207.95%
30.59 MUSD-29.01%
43.08 MUSD+19.64%
36.01 MUSD-30.21%
51.60 MUSD+313.00%
12.49 MUSD+92.39%
6.49 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

Total Assets of iBio is 99.11 M USD in 2026.

Total Assets of iBio changed from 23.19 M USD to 99.11 M USD, representing a 327.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets iBio since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's iBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iBio

All Key Metrics — iBio